Skip to main content
. 2018 Nov 23;10:6227–6236. doi: 10.2147/CMAR.S178979

Table 4.

Multivariate Cox regression analysis for patients with skeletal Ewing sarcoma

Characteristics Cancer-specific survival Overall survival
HR (95% CI) P-value HR (95% CI) P-value
Race 0.011 0.009
 White Ref. Ref.
 Non-White 1.334 (1.068–1.665) 0.011 1.329 (1.072–1.647) 0.009
Ethnicity 0.699 0.649
 Non-Hispanic Ref. Ref.
 Hispanic 1.037 (1.068–1.670) 0.699 1.042 (0.873–1.244) 0.649
Age (years) <0.001 <0.001
 0–19 Ref. Ref.
 20–39 1.544 (1.341–1.778) <0.001 1.538 (1.324–1.763) <0.001
 ≥40 2.180 (1.723–2.758) <0.001 2.348 (1.883–2.928) <0.001
Sex 0.084 0.048
 Male Ref. Ref.
 Female 0.877 (0.775–1.016) 0.084 0.877 (0.770–0.999) 0.048
Year of diagnosis <0.001 <0.001
 1973–1979 Ref. Ref.
 1980–1989 0.881 (0.691–1.124) 0.307 0.865 (0.688–1.089) 0.217
 1990–1999 0.598 (0.465–0.769) <0.001 0.594 (0.468–0.754) <0.001
 2000–2009 0.534 (0.422–0.676) <0.001 0.524 (0.419–0.655) <0.001
 2010–2014 0.493 (0.370–0.656) <0.001 0.504 (0.383–0.663) <0.001
Size (cm) <0.001 <0.001
 ≤10 Ref. Ref.
 >10 1.517 (1.243–1.851) <0.001 1.495 (1.231–1.816) <0.001
 Unknown 1.247 (1.055–1.473) 0.010 1.280 (1.090–1.503) 0.003
Lymph node 0.901 0.803
 Negative Ref. Ref.
 Positive 1.039 (0.591–1.828) 0.894 1.176 (0.705–1.960) 0.534
 Unknown 1.036 (0.890–1.205) 0.651 0.992 (0.859–1.146) 0.916
Surgery <0.001 <0.001
 No Ref. Ref.
 Yes 0.660 (0.576–0.756) <0.001 0.672 (0.590–0.766) <0.001
 Unknown 0.857 (0.624–1.178) 0.342 0.863 (0.637–1.170) 0.343
Stage <0.001 <0.001
 Non-distant Ref. Ref.
 Distant 2.528 (2.196–2.909) <0.001 2.359 (2.060–2.701) <0.001
 Unknown 1.158 (0.904–1.483) 0.246 1.163 (0.922–1.468) 0.202
Histologic type 0.412 0.430
 EWS Ref. Ref.
 PNET/Askin 0.842 (0.559–1.269) 0.412 0.854 (0.576–1.265) 0.430
Site <0.001 <0.001
 Axial Ref. Ref.
 Appendicular 0.801 (0.699–0.918) 0.001 0.784 (0.688–0.893) <0.001
 Bone, NOS 1.329 (0.974–1.813) 0.073 1.262 (0.929–1.714) 0.137

Abbreviations: EWS, Ewing sarcoma; PNET, peripheral primitive neuroectodermal tumors; Ref., reference.